JUPITER, Fla., April 7, 2011 /PRNewswire/ — Dyadic
International, Inc. (“Dyadic”) (OTC Pink: DYAI), a global
biotechnology company focused on the discovery, development,
manufacture and sale of enzyme and protein products for the
bioenergy, industrial enzyme and biopharmaceutical industries,
announced today that it has been issued U.S. Patent No. 7,906,309
entitled, “Expression-Regulating Sequences and Expression
Products in the Field of Filamentous Fungi” and U.S. Patent No.
7,892,812 entitled, “Chrysosporium Cellulase and Methods of
Use” by the United States Patent and Trademark Office
(“USPTO”).
(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO)
U.S. Patent No. 7,906,309
“Expression-Regulating Sequences and Expression Products in
the Field of Filamentous Fungi”
The inventions embodied by this patent are genes and their
corresponding enzymes from glycosyl hydrolase family 10 having
xylanase activity which are derived from Chysosporium fungal
strains. Other related applications claim cellobiohydrolases and
glyceraldehyde phosphate dehydrogenases. These enzymes have proven
to be effective in breaking down the major component of plant cell
walls, commonly known as lignocellulosic biomass, into fermentable
C5 sugars which can be used in the production of biofuels and
biochemicals. These genes and enzymes were isolated from
Dyadic’s patented and proprietary C1 fungus and identified through
the genome annotation project conducted by Dyadic in conjunction
with Scripps Florida.
Dyadic’s President and Chief Executive Officer, Mark Emalfarb,
stated, “This patent protects Dyadic’s ability to use its C1
technology to make fermentable C5 sugars in addition to the C6
sugars allowed by our previously awarded biofuels patent.”
U.S. Patent No. 7,892,812
“Chrysosporium Cellulase and Methods
‘/>”/>
